Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Therapy Post-ASCT in High-risk Aggressive Lymphoma
NCT03695055Phase 3Unknown
- Sponsor
- Fujian Medical University
- Start
- Jan 2014
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in aggressive lymphoma (3 arms), sponsored by Fujian Medical University. Primary endpoint: Relapse rate at 2 years. Status: unknown.
02
Drugs
rituximab
03
Conditions
aggressive lymphoma
Beyond the preview
Go deeper on NCT03695055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03695055.